From the Deputy Chief Medical Officer
Dr Paddy Woods

Circular HSC (SQSD) (NICE CG97 Addendum) 22/15

Subject: NICE Clinical Guideline CG97 – Lower urinary tract symptoms in men: assessment and management – Update/Addendum

Circular Reference: HSC (SQSD) (NICE CG97 Addendum) 22/15

Date of Issue: 17 June 2015

For action by:
Chief Executive of HSC Board – for distribution to:
All HSC Board Directors – for cascade to relevant staff

Director of Integrated Care, HSC Board – for cascade to:
Head of Pharmacy and Medicines Management
Family Practitioner Services Leads – for cascade to relevant Family Practitioner groups

Chief Executive of Public Health Agency – for distribution to:
Director of Public Health and Medical Director – for cascade to relevant staff
Director of Nursing and AHPs – for cascade to relevant staff

Chief Executives of HSC Trusts – for distribution to:
Medical Directors – for cascade to relevant staff
Directors of Nursing – for cascade to relevant staff
Heads of Pharmaceutical Services – for cascade to relevant staff
Directors of Acute Services – for cascade to relevant staff
HSC Clinical and Social Governance Leads
Directors of Social Services – for cascade to relevant staff
Directors of Finance – for cascade to relevant staff
AHP Leads – for cascade to relevant staff

Chief Executive, Regulation & Quality Improvement Authority – for cascade to: relevant independent healthcare establishments

Chief Executives of HSC Special Agencies and NDPBs

For Information to:
Chair of HSC Board
Chair of Public Health Agency
Chairs of HSC Trusts
Chair of RQIA
NICE Implementation Facilitator NI
Members of NI NICE Managers’ Forum

Superseded documents
None

Summary of Contents: This addendum adds a recommendation on phosphodiesterase-5 inhibitors to section 1.4 on drug treatment. A research recommendation on phosphodiesterase-5 inhibitors has also been added to section 2.5.

Enquiries:
Any enquiries about the content of this Circular should be addressed to:
Standards & Guidelines Quality Unit
DHSSPS
Room D1.4
Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ
SGU-NICEGuidance@dhsspsni.gov.uk

Implementation:
As per circular. Generally, Clinical Guidelines should be implemented within 12 months of endorsement.

Available to download from
http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance.htm
Dear Colleagues


The Department has recently reviewed the above NICE guidance and has formally endorsed it as applicable in Northern Ireland.

The original recommendations in CG97 (endorsed by the Department in June 2012) are already being implemented by the HSC Trusts. This circular and the actions it requires on implementation refer to the additional recommendations set out in the addendum.

In accordance with the process outlined in circular HSC (SQSD) 3/13 (http://www.dhsspsni.gov.uk/hsc_sqsd__3_13.pdf), the following actions should be taken:

1. HSC Board / PHA
   a. Identify a Professional Lead who will consider the commissioning implications of the addendum and co-ordinate with any other relevant commissioning teams. This Lead will identify any areas where regional planning / investment / commissioning are required, or where there is material risk to safety or quality. These will then be actioned immediately through normal commissioning arrangements or through bespoke arrangements reflecting the nature of the issue / risk.
   b. Ensure that relevant guidance is sent to the appropriate Family Practitioners.
   c. Seek positive assurance from the HSC Trusts that the required initial actions have been undertaken within a 3 month period, and that the addendum has been implemented within a further 9 months (unless otherwise notified by the HSC Trusts).
   d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, agree appropriate arrangements with HSC Trusts. Report to DHSSPS as required at 6 monthly accountability meetings.

2. HSC Trusts
   a. Proceed with targeted dissemination, agree a clinical/management lead to coordinate implementation and consider what has to be done to achieve implementation using a risk based assessment and baseline review as appropriate to support planning. These initial actions should be undertaken within a three month period.
   b. Implement the addendum within a further 9 months (apart from any elements where significant issues have been raised with the HSC Board/PHA).
   c. Provide positive assurances to the HSC Board that required initial actions have been taken within the 3 month planning period and that the addendum has been implemented within a further 9 months, where appropriate.
   d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, notify the HSC Board/PHA at the earliest opportunity through the bi-monthly director level meetings and agree appropriate arrangements with them to achieve implementation.
3. RQIA
   a. Disseminate the Guideline to the independent sector as appropriate.

4. HSC Special Agencies and NDPBs
   a. Take account of this Guideline in training and other developments as appropriate.

To inform the planning process, please find attached details from the Departmental review. You should consider and take account of other relevant Departmental policies and strategies in your planning, as well as any legislative / policy caveats identified in the course of the Departmental review.

A full current list of NICE guidance endorsed for application in Northern Ireland can be found on the Department's website (http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance/sqsd-guidance-nice-guidance.htm).

Dr Paddy Woods
Deputy Chief Medical Officer
## Appendix 1

### Endorsed NICE guidance - Details from Departmental review

<table>
<thead>
<tr>
<th>Reference Number</th>
<th>NICE Clinical Guidelines - CG97</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>Lower urinary tract symptoms in men: assessment and management – Update/Addendum</td>
</tr>
<tr>
<td><strong>Summary of guidance</strong></td>
<td>This clinical guideline offers evidence-based advice on the effective management of lower urinary tract symptoms (LUTS) in men. The addendum adds a recommendation on phosphodiesterase-5 inhibitors to section 1.4 on drug treatment. A research recommendation on phosphodiesterase-5 inhibitors has also been added to section 2.5. The addendum contains details of the methods and evidence used to develop these recommendations.</td>
</tr>
<tr>
<td><strong>Related strategically relevant DHSSPS policies</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Inter-Departmental interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Legislative / policy caveats</strong></td>
<td>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case. The Mental Capacity Act 2005 and the Department of Health document ‘Reference Guide to Consent for Treatment or Examination’ do not apply in NI, but work is under way to bring forward similar legislation for NI, incorporating mental capacity and mental health provisions. The DHSSPS guidance ‘Reference Guide to Consent for Examination, Treatment or Care (2003)’, which is available on the DHSSPS website, gives advice on determining whether a person has capacity and on what action may be taken where the person lacks capacity. Available from: <a href="http://www.dhsspsni.gov.uk/consent">http://www.dhsspsni.gov.uk/consent</a>.</td>
</tr>
</tbody>
</table>
Where the guidance indicates that informed consent should be obtained and documented, the DHSSPS guidance ‘Reference Guide to Consent for Examination, Treatment or Care (2003)’, which is available on the DHSSPS website, gives advice on the law concerning consent to intervention. Available from: http://www.dhsspsni.gov.uk/consent-referenceguide.pdf

It should be noted that this guidance contains some recommendations for off-label use of medicines. Trusts and practitioners must be aware of their responsibilities and ensure that appropriate policies are in place when medicines are used off-label.